Sanofi goes all in on Principia, paying $3.7B to take full control of late-phase MS asset Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program Buzzy anti-aging biotech Unity drops leading program after flop, shares in freefall Sponsored: Why Ethical Procurement Matters for Human Biospecimens Juno joint venture seeks IPO haul to bring CAR-Ts to China G1 Therapeutics' chemo companion nabs speedy FDA review More than a third of disrupted cancer trials back on track: report Amgen-partnered researchers treat diabetes in mice by silencing IL-2's inflammatory power Featured Story | By Nick Paul Taylor Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple sclerosis trials earlier this year. read more |
| |
|---|
|
Top Stories By Ben Adams Bristol Myers Squibb is paying nearly half a billion dollars in near-term and upfront payments to license Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program. read more By Ben Adams Just five months after Biogen’s head of early R&D Anirvan Ghosh left the company to take up the CEO post at Unity, its key leading knee pain program has failed and been thrown onto the trash heap. read more By BioIVT While the response to COVID-19 and other disease indications drives science forward, regulatory guidelines that ensure the safe and ethical treatment of patients continues to be critically important. read more By Nick Paul Taylor JW Therapeutics has filed the paperwork for a Hong Kong IPO. The Juno Therapeutics-WuXi AppTech joint venture is seeking money to advance a cell therapy pipeline led by anti-CD19 CAR-T JWCAR029. read more By Amirah Al Idrus Chemotherapy can kill off or contain fast-growing cancer cells, but it comes with well-known side effects that can limit its benefit. G1 Therapeutics aims to change that with its CDK4/6 inhibitor, which just snagged priority review from the FDA. With two co-promotion deals in the bag, the company is already gearing up for good news. read more By Ben Adams Oncology studies were some of the hardest hit in the first few months of the pandemic, but more than a third have now resumed. read more By Angus Liu Scientists at Benaroya Research Institute, in collaboration with researchers at Amgen, have engineered an IL-2 protein with a muted inflammatory effect. In mice with diabetes, the modified IL-2 can protect against autoimmunity and disease progression, they reported. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 